Clinical Trial Update: Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/2 trial evaluated the combination of ibrutinib, bortezomib, and Rituximab-CHOP in elderly patients with CD20+ Diffuse Large B-Cell Lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Ibrutinib (ibrutinib)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Prof. Dr. Clemens Schmitt | Conditions: Diffuse Large B Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED